



Akebia Therapeutics  
Investor Relations Department  
245 First Street  
Suite 1100  
Cambridge, MA 02142  
United States


[Visit IR website](#)   
[Sign-up for email alerts](#)

**NASDAQ: AKBA**

Last Trade:	13.43
Trade Time:	4:00 PM ET May 26, 2017
Change:	-0.42 (3.032%)
Day Range	13.36 - 13.83
52-Week Range	7.00 - 15.88
Volume	321,121

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Stock Performance



### Press Releases [\[ View all \]](#)

May 25, 2017

[Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer](#)

May 24, 2017

[Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents](#)

May 15, 2017

[Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval](#)

May 9, 2017

[Akebia Announces First Quarter 2017 Financial Results](#)

May 4, 2017

[Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

### Financials [\[ View all \]](#)

Mar 6, 2017

[Annual Report \(10-K\)](#)

May 1, 2017

[Proxy Statement \(DEF 14A\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 9, 2016

[Quarterly Report \(10-Q\)](#)

Aug 8, 2016

[Quarterly Report \(10-Q\)](#)